Stock NPCE NEUROPACE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages NeuroPace, Inc.

Equities

NPCE

US6412881053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
6.91 USD +5.66% Intraday chart for NeuroPace, Inc. -8.23% -32.98%
May. 13 Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating MT
May. 08 NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NeuroPace to Participate in Two Healthcare Conferences in May
Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating
NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Transcript : NeuroPace, Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $18.1M, vs. Street Est of $17.3M
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
North American Morning Briefing : Inflation -2-
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating
NeuroPace Shares Decline Following Q4 Financial Results
NeuroPace, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Transcript : NeuroPace, Inc., Q4 2023 Earnings Call, Mar 05, 2024
NeuroPace, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
NeuroPace, Inc. Provides Earnings Guidance for the Year 2024
Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NPCE Stock
  4. News NeuroPace, Inc.
  5. Other languages